Back to Search Start Over

Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice.

Authors :
Chang S
Kim YH
Kim YJ
Kim YW
Moon S
Lee YY
Jung JS
Kim Y
Jung HE
Kim TJ
Cheong TC
Moon HJ
Cho JA
Kim HR
Han D
Na Y
Seok SH
Cho NH
Lee HC
Nam EH
Cho H
Choi M
Minato N
Seong SY
Source :
Frontiers in immunology [Front Immunol] 2018 Sep 18; Vol. 9, pp. 1984. Date of Electronic Publication: 2018 Sep 18 (Print Publication: 2018).
Publication Year :
2018

Abstract

Bile acids (BAs) control metabolism and inflammation by interacting with several receptors. Here, we report that intravenous infusion of taurodeoxycholate (TDCA) decreases serum pro-inflammatory cytokines, normalizes hypotension, protects against renal injury, and prolongs mouse survival during sepsis. TDCA increases the number of granulocytic myeloid-derived suppressor cells (MDSC <subscript>LT</subscript> ) distinctive from MDSCs obtained without TDCA treatment (MDSC <subscript>L</subscript> ) in the spleen of septic mice. FACS-sorted MDSC <subscript>LT</subscript> cells suppress T-cell proliferation and confer protection against sepsis when adoptively transferred better than MDSC <subscript>L</subscript> . Proteogenomic analysis indicated that TDCA controls chromatin silencing, alternative splicing, and translation of the immune proteome of MDSC <subscript>LT</subscript> , which increases the expression of anti-inflammatory molecules such as oncostatin, lactoferrin and CD244. TDCA also decreases the expression of pro-inflammatory molecules such as neutrophil elastase. These findings suggest that TDCA globally edits the proteome to increase the number of MDSC <subscript>LT</subscript> cells and affect their immune-regulatory functions to resolve systemic inflammation during sepsis.

Details

Language :
English
ISSN :
1664-3224
Volume :
9
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
30279688
Full Text :
https://doi.org/10.3389/fimmu.2018.01984